AstraZeneca setting up R&D centre in Cambridge, Massachusetts
LONDON: AstraZeneca has announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub. It will be a strategic R&D...
AstraZeneca signs multi-billion dollar deal with Ionis Pharmaceuticals
LONDON, UK: AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-L. The companies will jointly develop and...
AstraZeneca to transfer global rights for Eklira and Duaklir to Covis Pharma
LONDON, UK: AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma Group (Covis Pharma). Both...
AstraZeneca to fully acquire Caelum Biosciences
LONDON, UK: AstraZeneca‘s Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a potentially first-in-class fibril-reactive monoclonal antibody (mAb)...
AstraZeneca plans $360 million Irish manufacturing investment
LONDON, UK: AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s...
AstraZeneca complete acquisition of Alexion Pharmaceuticals
LONDON, UK: AstraZeneca today completed the acquisition of Alexion Pharmaceuticals Inc. The closing of the acquisition marks the Company’s entry into medicines for rare diseases...
AstraZeneca appoints Aradhana Sarin as new Chief Financial Officer
LONDON, UK: AstraZeneca PLC has appointed Aradhana Sarin as an Executive Director and Chief Financial Officer, conditional upon closing of AstraZeneca’s acquisition of Alexion Pharmaceuticals...
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
LONDON: AstraZeneca‘s COVID-19 vaccine, Vaxzevria, formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18...
AstraZeneca US vaccine trial met primary endpoint
LONDON: The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing...
AstraZeneca notifies non-executive board changes
LONDON: AstraZeneca PLC announced today that Non-Executive Directors Geneviève Berger and Graham Chipchase intend to retire from the Board at the conclusion of the Company’s...
AstraZeneca agrees to divest Viela shareholding for upto $780mn
STOCKHOLM: AstraZeneca Plc has agreed, subject to certain limited exceptions, to divest its 26.7% ownership in Viela Bio Inc. as part of the proposed acquisition...
COVID-19 Vaccine AstraZeneca authorised for use in the EU
LONDON: AstraZeneca‘s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by...